tetano
Editor, Senior Moderator
J Allergy Clin Immunol. 2015 Feb 1. pii: S0091-6749(15)00005-6. doi: 10.1016/j.jaci.2014.12.1925. [Epub ahead of print]
[h=1]Safety of live attenuated influenza vaccine in atopic children with egg allergy.[/h] Turner PJ[SUP]1[/SUP], Southern J[SUP]2[/SUP], Andrews NJ[SUP]2[/SUP], Miller E[SUP]2[/SUP], Erlewyn-Lajeunesse M[SUP]3[/SUP]; SNIFFLE Study Investigators.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Live attenuated influenza vaccine (LAIV) is an intranasal vaccine recently incorporated into the United Kingdom immunization schedule. However, it contains egg protein and, in the absence of safety data, is contraindicated in patients with egg allergy. Furthermore, North American guidelines recommend against its use in asthmatic children.
[h=4]OBJECTIVE:[/h] We sought to assess the safety of LAIV in children with egg allergy.
[h=4]METHODS:[/h] We performed a prospective, multicenter, open-label, phase IV intervention study involving 11 secondary/tertiary centers in the United Kingdom. Children with egg allergy (defined as a convincing clinical reaction to egg within the past 12 months and/or >95% likelihood of clinical egg allergy as per published criteria) were recruited. LAIV was administered under medical supervision, with observation for 1 hour and telephone follow-up 72 hours later.
[h=4]RESULTS:[/h] Four hundred thirty-three doses were administered to 282 children with egg allergy (median, 4.9 years; range, 2-17 years); 115 (41%) had experienced prior anaphylaxis to egg. A physician's diagnosis of asthma/recurrent wheezing was noted in 67%, and 51% were receiving regular preventer therapy. There were no systemic allergic reactions (upper 95% CI for population, 1.3%). Eight children experienced mild self-limiting symptoms, which might have been due an IgE-mediated allergic reaction. Twenty-six (9.4%; 95% CI for population, 6.2% to 13.4%) children experienced lower respiratory tract symptoms within 72 hours, including 13 with parent-reported wheeze. None of these episodes required medical intervention beyond routine treatment.
[h=4]CONCLUSIONS:[/h] In contrast to current recommendations, LAIV appears to be safe for use in children with egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze.
Copyright ? 2015 The Authors. Published by Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] Egg allergy; asthma; live attenuated influenza vaccine; recurrent wheezing; safety
PMID: 25684279 [PubMed - as supplied by publisher] Free full text
[h=1]Safety of live attenuated influenza vaccine in atopic children with egg allergy.[/h] Turner PJ[SUP]1[/SUP], Southern J[SUP]2[/SUP], Andrews NJ[SUP]2[/SUP], Miller E[SUP]2[/SUP], Erlewyn-Lajeunesse M[SUP]3[/SUP]; SNIFFLE Study Investigators.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Live attenuated influenza vaccine (LAIV) is an intranasal vaccine recently incorporated into the United Kingdom immunization schedule. However, it contains egg protein and, in the absence of safety data, is contraindicated in patients with egg allergy. Furthermore, North American guidelines recommend against its use in asthmatic children.
[h=4]OBJECTIVE:[/h] We sought to assess the safety of LAIV in children with egg allergy.
[h=4]METHODS:[/h] We performed a prospective, multicenter, open-label, phase IV intervention study involving 11 secondary/tertiary centers in the United Kingdom. Children with egg allergy (defined as a convincing clinical reaction to egg within the past 12 months and/or >95% likelihood of clinical egg allergy as per published criteria) were recruited. LAIV was administered under medical supervision, with observation for 1 hour and telephone follow-up 72 hours later.
[h=4]RESULTS:[/h] Four hundred thirty-three doses were administered to 282 children with egg allergy (median, 4.9 years; range, 2-17 years); 115 (41%) had experienced prior anaphylaxis to egg. A physician's diagnosis of asthma/recurrent wheezing was noted in 67%, and 51% were receiving regular preventer therapy. There were no systemic allergic reactions (upper 95% CI for population, 1.3%). Eight children experienced mild self-limiting symptoms, which might have been due an IgE-mediated allergic reaction. Twenty-six (9.4%; 95% CI for population, 6.2% to 13.4%) children experienced lower respiratory tract symptoms within 72 hours, including 13 with parent-reported wheeze. None of these episodes required medical intervention beyond routine treatment.
[h=4]CONCLUSIONS:[/h] In contrast to current recommendations, LAIV appears to be safe for use in children with egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze.
Copyright ? 2015 The Authors. Published by Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] Egg allergy; asthma; live attenuated influenza vaccine; recurrent wheezing; safety
PMID: 25684279 [PubMed - as supplied by publisher] Free full text